NeuMoDxMolecular, Ann Arbor, Mich, a molecular diagnostics company focused on central laboratory customers, has introduced CE-marked assays for cytomegalovirus (CMV) and Epstein-Barr virus (EBV). The assays integrate the entire molecular diagnostic process, with the first result available in approximately 1 hour. Operators can load patient samples in a continuous, random-access workflow for sample processing, with a walkaway window of up to 8 hours.
CMV and EBV are herpes viruses found in up to 90% of the adult population. Usually latent, the presence of these viruses may lead to serious complications for patients receiving solid organ transplants. Specifically, posttransplant lymphoproliferative disease (PTLD) is a life-threatening complication of solid organ transplantation. It is associated with active replication of EBV when an organ from a seropositive donor is transplanted or with reactivation during treatment with immunosuppressive drugs administered to the transplant recipient. The risk of complications requires transplant recipients to receive regular monitoring for CMV and EBV so that appropriate therapy can be administered in order to avoid or treat the complications associated with PTLD.
Daniel Harma, NeuMoDx Molecular.
“Providing fast and accurate monitoring of CMV and EBV is critical in the long-term care of transplant recipients.” says Dan Harma, chief commercial officer at NeuMoDx. “Laboratories around the world will be able to deliver high-quality results to clinicians and the patients they serve in a more rapid and efficient manner.”
The proprietary NeuDry reagents used with the systems require no refrigeration and have an on-board stability of up to 60 days and ambient temperature shelf life of greater than 1 year. The unitized format of the NeuDry reagents increases operating efficiency while minimizing the waste associated with systems requiring manual reconstitution and use of bulk lyophilized reagents.
For more information visit NeuMoDx.
